Home > Search Results

Results: 1 to 20 of 74

Clear

The study found evidence to suggest that integrated continuous glucose monitoring insulin pump therapy systems are more clinically effective in patients with type 1 diabetes than stand-alone treatments. However, based on the evidence available, these integrated systems are unlikely to be cost-effective in comparison with stand-alone insulin delivery and monitoring. Further research on the clinical effectiveness and cost-effectiveness of these integrated systems in different populations is warranted.

Health Technology Assessment - NIHR Journals Library.

Version: February 2016

Nausea and vomiting are major concerns for patients undergoing chemotherapy, radiation therapy and surgery with general anesthesia. Risk factors associated with chemotherapy-induced nausea and vomiting include emetogenicity of the chemotherapy regimen, dose, speed of intravenous infusion, female gender, age under 50 years, history of ethanol consumption, and history of prior chemotherapy. Factors predictive of radiation therapy-induced nausea and vomiting include site of irradiation (in particular, total body irradiation and radiation fields that include the abdomen), total field size, dose per fraction, age, and predisposition for emesis (history of sickness during pregnancy or motion sickness). Female gender, a history of motion sickness or prior postoperative nausea and vomiting, nonsmoking status, and use of postoperative opioids have been suggested as factors predictive of postoperative nausea and vomiting. The objective of this review was to evaluate the comparative effectiveness and harms of newer antiemetic drugs including the 5-HT3 and NK-1 antagonists.

Drug Class Reviews - Oregon Health & Science University.

Version: January 2009

The study was unable to compare the clinical and cost-effectiveness of platinum-based therapies with non-platinum-based therapies for platinum sensitive ovarian cancer. In people with platinum-sensitive disease, paclitaxel plus platinum could be considered cost-effective compared with platinum therapies alone at a threshold of £30,000 per additional quality-adjusted life-year. In people with disease which is resistant or refractory to platinum it is unlikely that topotecan would be considered cost-effective compared with pegylated liposomal doxorubicin hydrochloride.

Health Technology Assessment - NIHR Journals Library.

Version: January 2015

Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: January 19, 2018

The study found that erythropoiesis-stimulating agents could be cost-effective for treating cancer treatment-induced anaemia when used closer to licence but that there is considerable uncertainty, mainly because of unknown impacts on overall survival.

Health Technology Assessment - NIHR Journals Library.

Version: February 2016

The term “cancer of unknown primary” refers to a condition in which a patient has metastatic malignancy without an identified primary source. This is a very heterogeneous disease in which the type of tumour, the extent of spread, and the outcome of treatment all vary widely. When categorising patients with cancer of unknown primary, one important factor initially considered is the cell type of origin of the metastatic disease. The majority of patients have malignancy which appears to derive from epithelial cells, and hence are regarded as having carcinoma of unknown primary. Patients with tumours of non-epithelial lineage (melanoma, sarcoma, lymphoma, germ-cell) form a distinct and important minority, since subsequent management can often be satisfactorily undertaken even in the absence of an identifiable primary source. Such patients are not considered in this guideline, since their care is adequately defined in existing guidelines for their specific tumour type. The term “carcinoma of unknown primary” (CUP) is used henceforth to refer to those patients with metastatic malignancy of epithelial, neuroendocrine or undifferentiated lineage whose investigation and management is considered within the scope of this guideline.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: July 2010

Lung cancer is the leading cause of cancer death in both men and women in the United States, and male Veterans seeking care at VA hospitals have a much higher age-specific incidence of lung cancer than males in the general population. The personal and economic significance of lung cancer has led to a vast research endeavor to try and identify new and more effective treatments. Most patients with lung cancer are diagnosed when the cancer is already advanced (stage IIIB or IV), and they are no longer candidates for surgical resection. Small cell lung cancer and non-small cell lung cancer (NSCLC) are different diseases in terms of treatment. Until recently, all therapies for advanced NSCLC were based on their cytotoxic properties. In the last few years, several novel agents aimed at specific molecular targets have been developed. This review was requested to evaluate the current evidence on the effectiveness and cost-effectiveness of treatments for advanced lung cancer.

Evidence-based Synthesis Program - Department of Veterans Affairs (US).

Version: October 2012

This guidance updates and replaces NICE clinical guideline 24 (published February 2005).

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: April 2011

Expert-reviewed information summary about the treatment of non-small cell lung cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: March 20, 2018

Study provides a comprehensive framework of information for three subpopulations of patients with non-small cell lung cancer that clinicians can refer to as they attempt to balance patient factors, available treatments, treatment costs and adverse events in their daily decision-making.

Health Technology Assessment - NIHR Journals Library.

Version: July 2013

There are two types of stool antigen tests for the diagnosis of H. pylori infection, one based on enzyme immunoassay (EIA) and the other based on immunochromatography (ICA). Both types of tests can be operated using either monoclonal antibody or polyclonal antibodies. Although both are highly sensitive and specific, the EIA-based tests appears to be more accurate than the ICA-based tests. However, the ICA-based tests do not required specialized equipment, are easy to use, and are useful for rapid diagnosis of H. pylori infection.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: January 8, 2015

Lung cancer is the leading cause of cancer death and almost 75% of people are incurable at diagnosis. Non‐small cell is the most common type of lung cancer (almost 90% of all lung cancer cases). For many of these people, chemotherapy is a good treatment option and it is associated with longer survival and better quality of life. However, treatment for people with advanced non‐small cell lung cancer is palliative, in that it provides relief from pain and other distressing symptoms. Treatments that include cisplatin or carboplatin plus another drug are the most widely used drug combinations, but they can be associated with undesirable toxicity. Thus, it would be desirable to have a treatment that is just as effective but with less toxicity.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: August 16, 2013

Expert-reviewed information summary about the treatment of small cell lung cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: February 9, 2018

Metastatic squamous neck cancer with occult primary in adults occurs when squamous cell cancer spreads to lymph nodes in the neck from an undetectable primary tumor. Treatment includes surgery and radiation therapy. Learn about the diagnosis, survival, staging, and treatment of these tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: February 8, 2018

Expert-reviewed information summary about the treatment of bladder cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 12, 2018

This clinical guideline was commissioned by NICE and developed by the National Collaborating Centre for Mental Health. It sets out clear, evidenceand consensus-based recommendations for healthcare staff on how to treat and manage depression in adults with a chronic physical health problem.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2010

Bladder cancer is the seventh most common cancer in the UK, with just over 10,000 cases diagnosed each year (CRUK, 2013a). These are unevenly split between men (fourth most common cancer) and women (11th most common cancer).

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: February 2015

Expert-reviewed information summary about the treatment of childhood extracranial germ cell tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 5, 2018

We compared the effectiveness and harms of anticonvulsants, tricyclic antidepressants, serotonin–norepinephrine reuptake inhibitors (SNRIs), and the lidocaine patchin adults with neuropathic pain.

Drug Class Reviews - Oregon Health & Science University.

Version: June 2011

Expert-reviewed information summary about the treatment of gallbladder cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: January 25, 2018

Systematic Reviews in PubMed

See all (23)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...